Cosmo Pharmaceuticals N.V (C43) — Cash Flow-to-Debt Ratio
Cosmo Pharmaceuticals N.V (C43) has a Cash Flow-to-Debt Ratio of 0.02x as of June 2022, meaning its operating cash flow of €6.28 Million could theoretically repay 0% of its total liabilities (€296.03 Million) in one year. See Cosmo Pharmaceuticals N.V (C43) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cosmo Pharmaceuticals N.V Cash Flow-to-Debt Ratio (2016–2025)
Historical debt coverage capacity for Cosmo Pharmaceuticals N.V across 10 annual periods. Also explore Cosmo Pharmaceuticals N.V equity growth rate to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Cosmo Pharmaceuticals N.V (2016–2025)
Year-by-year debt coverage analysis for Cosmo Pharmaceuticals N.V. For market capitalisation and broader financial context, see market value of Cosmo Pharmaceuticals N.V.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.10x | €-12.48 Million | €123.46 Million | ▼ -108.8% |
| 2024 | 1.15x | €162.41 Million | €141.68 Million | ▲ +317.4% |
| 2023 | 0.27x | €33.62 Million | €122.42 Million | ▲ +144.5% |
| 2022 | 0.11x | €33.23 Million | €295.80 Million | ▲ +160.9% |
| 2021 | 0.04x | €12.61 Million | €292.88 Million | ▼ -35.0% |
| 2020 | 0.07x | €12.98 Million | €196.04 Million | ▲ +167.3% |
| 2019 | -0.10x | €-18.85 Million | €191.43 Million | ▼ -75.2% |
| 2018 | -0.06x | €-10.16 Million | €180.83 Million | ▲ +83.4% |
| 2017 | -0.34x | €-9.43 Million | €27.86 Million | ▼ -143.6% |
| 2016 | 0.78x | €21.69 Million | €27.92 Million | — |